Global Antihelminthics Market Research Report: Information By Application (Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis, and Others), By Type (Benzimidazoles, Abamectin, Salicylanilides, Praziquantel, and Others), By End User (Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032.
According to a new report by IMIR Market Research on Global Antihelminthics Market Size was valued at USD 1.9 Billion in 2022. The Antihelminthics market Type is projected to grow from USD 1.4 Billion in 2023 to USD 3.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.30% during the forecast period (2023 - 2032).
An increase in global infection rates and rising healthcare infrastructure investments, are the key market drivers enhancing the market growth.
The Antihelminthics market research report comprises a thorough examination of the current and future scenario of this industry vertical. The research highlights major trends and opportunities, as well as challenges, for various segments and sub-segments, while broadening the company horizon. The study report also includes extensive information based on past and present patterns across several industry verticals to help find various expansion prospects. Throughout the forecast period, several estimations regarding market share, market size, and industry growth rate are presented. The research includes information on competitive analysis as well as consumption habits and pricing strategies depending on the Antihelminthics market.
Antihelminthics Market Trends
As helminth infections brought on by roundworm, whipworm, hookworm, and other worms become more prevalent, the market for anthelmintics is anticipated to grow. Many parasitic worm species propagate helminth illnesses through the soil. The WHO predicts that more than 1.9 billion people worldwide had helminth infections as of March 2020, which were transmitted through the soil. Ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale are a few of the principal disease-causing species of hookworms. Additionally, 600 million individuals globally are thought to be harmed by S. stercoralis. Other factors that contribute to the increase in soil-transmitted helminth infections around the world include poor sanitation and hygiene. The market for anthelmintics is growing, and one of the key factors affecting how quickly it does so is the rising cost of healthcare. The efforts of various government organizations to improve the healthcare infrastructure by increasing funding would have an additional impact on market dynamics.
Government initiatives and a paradigm change toward assisting in the management of helminth illnesses globally are expected to cause the market for anthelmintic medications to expand. For instance, the National Deworming Day is a big initiative by the Ministry of Health and Family Welfare to eradicate worms in India. According to the WHO, parasitic intestinal worms can infect 241 million Indian children between the ages of one and 14. Therefore, recommendations from the government to raise awareness and eliminate helminth infection are expected. Additionally, as the global population ages and the number of afflicted people rises, the market for anthelmintics will expand. Favorable reimbursement procedures will hasten market growth as well.
There is a lot of interest in the creation of anthelmintic drugs that can treat nematodes with plant-based ingredients. Nematodes, an intestinal parasite, are today a major issue in both people and animals. In the market for anthelmintic drugs, which is anticipated to expand at a CAGR of 5% over the course of the forecast period, animals thus hold a bigger revenue share than people. An obstacle for pharmaceutical companies is the resistance to anthelmintic drugs in both humans and animals. As a result, companies are using elements from medicinal plants to create brand-new anthelmintic drugs. Companies in the market for anthelmintic medications are stepping up their efforts to investigate the biologically active components of medicinal plants that have properties akin to those of drugs and have the potential to be successful in treating intestinal parasitic worms in both people and animals. As a result, drugs derived from medicinal plants, such as artemether, tiopropium, and galantamine, generate revenue for pharmaceutical companies. Thus, driving the Antihelminthics market revenue.
Antihelminthics Industry Developments
April 2019: The new drug VERMOX (Mebendazole) CHEWABLE from Janssen Pharmaceuticals Inc. has been prequalified by the WHO for intestinal worms. Following the WHO prequalification, this medicine is probably available to infants under the age of one, especially in countries with a high burden.
September 2018: According to Cipla, the Abbreviated New Drug Application (ANDA) for albendazole 200 mg tablet has finally been authorized.
Scope of Antihelminthics Market Report
A recent market research report added to repository of Intellectual Market Insights Research is an in-depth analysis of Global Antihelminthics Market. On the basis of historic growth analysis and current scenario of Antihelminthics market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that facilitate deeper understanding of multiple aspects of global Antihelminthics market. This further helps users with their developmental strategy.
Antihelminthics Key Market Players & Competitive Insights
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Antihelminthics market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Antihelminthics sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Aerospace Foam industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Antihelminthics sector. Major players in the Antihelminthics market, including Abbott, Novartis AG, ZEISS International , Johnson & Johnson Services, Inc., Sanofi, Merck & Co., Inc., GlaxoSmithKline plc., Astellas Pharma Inc., Bayer AG, Mentis Pharma Ltd., Pfizer Inc., Sanofi, ALLERGAN, and AstraZeneca, are attempting to increase market demand by investing in research and development operations.
Zoetis Inc. (Zoetis) is an animal healthcare company that conducts research, develops, produces, and sells drugs, immunizations, and diagnostic equipment for livestock and companion animals. Its products are supplemented by biodevices, genetic diagnostics, and precision cattle husbandry. The company sells vaccines, parasiticides, anti-infective medications, and medicated feed additives among other things. It also offers contract manufacturing services to other parties via its client supply services (CSS) organization. The company has manufacturing facilities all over the world, and it sells products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through direct marketing channels and distributors in the Americas, Europe, Africa, Asia, and Australia. The company's headquarters are located in Parsippany, New Jersey, in the United States. The FDA authorized Zoetis' Simparica Trio in February 2020 as a drug combination to treat heartworm disease, roundworms, rickets, hookworms, and fleas in dogs.
Amneal Pharmaceuticals Inc. (Amneal), formerly Amneal Pharmaceuticals LLC, is a pharmaceutical company that creates, produces, advertises, and distributes prescription products. It provides both generic and specialized pharmaceutical items. Additionally, the business distributes medicines for conditions related to the central nervous system, oncology, inflammation and pain, endocrinology, and parasitic infections, including Activella, Albenza, Dexedrine, Nizatidine Oral Solution, and Pyridiu. Amneal sells products in a variety of dosage forms, such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids, and other device-driven products. There are operational hubs for the business in India, Switzerland, Ireland, and the United Kingdom. Amneal's headquarters are in the city of Bridgewater in the United States. Amneal Pharmaceuticals, Inc. was successfully formed in May 2018 through the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. This agreement should boost the generic sector, elevating Amneal to the fifth-largest generic company in the US.
Key Companies in the Antihelminthics market include
Antihelminthics Market Segmentation Analysis
Antihelminthics Market Segment Insights
The global Antihelminthics market segmentation, based on Application, includes schistosomiasis, fasciolasis, filariasis, angiostrongylosis, ascariasis, giardiasis, and others. Schistosomiasis segment dominated the global market in 2022. This is due to the fact that schistosomiasis is becoming more widespread in many tropical and subtropical developing countries. Schistosomiasis continues to be a substantial health problem with serious socioeconomic repercussions in areas where sanitation and control efforts are weak and the majority of the population lives in poverty. A variety of factors that are frequently connected to the national spread of diseases include schistosomiasis. Some of these causes include low socioeconomic status, a lack of access to clean water, a lack of fundamental infrastructure, relatively poor housing quality, and inadequate environmental sanitation.
The global Antihelminthics market segmentation, based on Type, includes benzimidazoles, abamectin, salicylanilides, praziquantel, and others. Benzimidazoles segment dominated the global market in 2022. This is because prodrugs have lengthy half-lives and don't easily breakdown into inactive byproducts. Since effective quantities are maintained for a prolonged period of time in the stomach and plasma, it is more effective against immature and arrested larvae as well as adult nematodes, especially lungworms.
The global Antihelminthics market segmentation, based on End User, includes hospitals, clinics, and others. Hospitals segment dominated the global Antihelminthics market in 2022. Antihelminthic medications' expanding popularity and efforts by both public and private organizations to construct cutting-edge hospitals are the main forces behind market expansion.
By region, Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Antihelminthics Market dominated this market in 2022 (45.80%). This is due to the fact that helminth infections are getting more widespread, and growing healthcare costs will further speed up this market's expansion. Due to the increasing attention that major market players are giving to developing technology, the industry growth rate in this area will also increase. Further, In the North American area, the U.S. Antihelminthics market had the biggest market share, while the Canada Antihelminthics market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Europe Antihelminthics market accounted for the healthy market share in 2022. The high aging population, the accessibility of research funds, and government support for R&D will boost the market. Further, In the European region, the German Antihelminthics market had the biggest market share, and the U.K. Antihelminthics market had the quickest rate of growth.
The Asia Pacific Antihelminthics market is expected to register significant growth from 2023 to 2032. This is a result of the rapidly expanding senior population in the area. The market's growth in this area will also be accelerated by expanding government initiatives and the expansion of the healthcare sector's infrastructure. Moreover, In the Asia-Pacific region, the Indian Antihelminthics market had the quickest rate of growth while China's Antihelminthics market had the greatest market share.
Antihelminthics Market Report is also available for below Regions and Country Please Ask for that
Points Covered in the Report
Key Questions
Research Scope of Antihelminthics Market
Antihelminthics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends:
Frequently Asked Questions
• The Schistosomiasis Application had the largest share in the global market.
• The Benzimidazoles Type dominated the market in 2022.
• The key players in the market are Abbott, Novartis AG, ZEISS International , Johnson & Johnson Services, Inc., Sanofi, Merck & Co., Inc., GlaxoSmithKline plc., Astellas Pharma Inc., Bayer AG, Mentis Pharma Ltd., Pfizer Inc., Sanofi, ALLERGAN, and AstraZeneca
• North America had the largest share in the global market
• The global market is projected to grow at a CAGR of 9.30% during the forecast period, 2023-2032.
• The global Antihelminthics market size was valued at USD 1.9 Billion in 2022.
Want to Review Complete Market Research Report
Customize this Report
Related Reports
Liver Fibrosis Drug Market Demand, Growth, Size Industry Outlook Report
October, 2024